Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery.
Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business.
In July 2020, he joined founder and then-CEO at Qnovia (then Respira Technologies) Mario Danek as chief operating officer. Now CEO, with Danek as chief technology officer, Quigley leads the company as it looks to bring a prescription smoking cessation therapy to market.
Quigley acknowledged the potential applications Qnovia could pursue with its inhaled therapeutic technology. For now, though, the focus is firmly on pursuing FDA approval for what would be the first inhalable prescription smoking cessation therapy.
“I joined Qnovia because of what I learned when I first met Mario Danek,” Quigley told Drug Delivery Business News. “He explained this innovation he created. He’s taken proven medical device technology and been able to imbue it with form factors for better compliance, better adoption and better patient outcomes.”
Get the full story at our sister site, Drug Delivery Business News.
